Ipilimumab: tested in a combination
412 studies: another drug in the study is under test too. Page 3 of 5. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCompletedNCT01681212Phase 2Results postedReport a problem
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results postedReport a problem
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial CarcinomaCompletedNCT01524991Phase 2Results postedReport a problem
- Yervoy With Sylatron Unresectable Stage 3 or 4 MelanomaCompletedNCT01496807Phase 1Results postedReport a problem
- Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01473940Phase 1Results postedReport a problem
- Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results postedReport a problem
- Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityCompletedNCT01323517Phase 2Results postedReport a problem
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT01274338Phase 3Results postedReport a problem
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT01024231Phase 1Results postedReport a problem
- Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineCompletedNCT00796991Phase 1Results postedReport a problem
- MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3Results postedReport a problem
- Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCompletedNCT00084656Phase 2Results postedReport a problem
- First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell CarcinomaCompletedNCT07947277Phase 2Report a problem
- Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.Active, not recruitingNCT07654530Phase 2Report a problem
- Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaActive, not recruitingNCT06566391Phase 2Report a problem
- A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerWithdrawnNCT06410534Phase 2Report a problem
- Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaWithdrawnNCT06365619Phase 2Report a problem
- A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent GlioblastomaActive, not recruitingNCT06097975Phase 1Report a problem
- Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1Report a problem
- Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1Report a problem
- Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer PatientsWithdrawnNCT05504642Phase 2Report a problem
- Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnNCT05457959Phase 1Report a problem
- Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsCompletedNCT05302921Phase 2Report a problem
- CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2Report a problem
- Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerCompletedNCT05219435Phase 2Report a problem
- CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyActive, not recruitingNCT05215470Phase 2Report a problem
- Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UCActive, not recruitingNCT05200988Phase 2Report a problem
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabTerminatedNCT05199285Phase 2Report a problem
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1Report a problem
- Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1Report a problem
- EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCActive, not recruitingNCT05150236Phase 2Report a problem
- Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell CancerActive, not recruitingNCT05148546Phase 2Report a problem
- A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT05144854Phase 3Report a problem
- A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsCompletedNCT05136677Phase 2Report a problem
- Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.TerminatedNCT05116917Phase 2Report a problem
- Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesActive, not recruitingNCT05012254Phase 2Report a problem
- Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaCompletedNCT05004025Phase 1Report a problem
- Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2Report a problem
- Combination Immunotherapy in Rare Cancers Under InvesTigationActive, not recruitingNCT04969887Phase 2Report a problem
- Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaTerminatedNCT04967196Phase 1Report a problem
- Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerTerminatedNCT04966676Phase 2Report a problem
- Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaActive, not recruitingNCT04949113Phase 3Report a problem
- Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2Report a problem
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1Report a problem
- Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerActive, not recruitingNCT04751370Phase 2Report a problem
- Metastatic Solid Cancer Clinical TrialCompletedNCT04739618Phase 2Report a problem
- Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.Active, not recruitingNCT04730544Phase 2Report a problem
- Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE TrialCompletedNCT04721301Phase 1Report a problem
- Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate CancerCompletedNCT04717154Phase 2Report a problem
- A Phase 2 Trial for Patients With Metastatic Solid CancerActive, not recruitingNCT04713371Phase 2Report a problem
- A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerActive, not recruitingNCT04709276Phase 2Report a problem
- Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to SurgeryCompletedNCT04620200Phase 2Report a problem
- Surgical Nivolumab And Ipilimumab For Recurrent GBMActive, not recruitingNCT04606316Phase 1Report a problem
- Nivolumab+Ipilimumab+RT in MSS mCRCStatus unknownNCT04575922Phase 2Report a problem
- Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsStatus unknownNCT04571632Phase 2Report a problem
- IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2Report a problem
- Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaActive, not recruitingNCT04551430Phase 2Report a problem
- Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1Report a problem
- Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2Report a problem
- Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath TumorCompletedNCT04465643Phase 1Report a problem
- Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma MetastasesCompletedNCT04463368Phase 1Report a problem
- FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal CancerWithdrawnNCT04430985Phase 2Report a problem
- Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected PrimaryTerminatedNCT04429321Phase 1Report a problem
- Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2Report a problem
- Nivolumab + Ipilimumab + Radiation in MSS Pancreatic CancerActive, not recruitingNCT04361162Phase 2Report a problem
- A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesTerminatedNCT04311710Phase 1Report a problem
- PHP and Immunotherapy in Metastasized UMActive, not recruitingNCT04283890Phase 1/2Report a problem
- Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerTerminatedNCT04258150Phase 2Report a problem
- COL Immunotherapy Before Radiochimio + IpilimumabCompletedNCT04256213Not applicableReport a problem
- Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.CompletedNCT04247165Phase 1/2Report a problem
- Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTerminatedNCT04185311Phase 1Report a problem
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2Report a problem
- Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2Report a problem
- A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2Report a problem
- Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1Report a problem
- Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.Status unknownNCT04134182Phase 2Report a problem
- Nivolumab/Ipilimumab in Second Line CUP-syndromeStatus unknownNCT04131621Phase 2Report a problem
- Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerCompletedNCT04124601Phase 2Report a problem
- A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2Report a problem
- Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck CancerActive, not recruitingNCT04080804Phase 2Report a problem
- Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCActive, not recruitingNCT04043195Phase 1/2Report a problem
- Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsCompletedNCT04042753Phase 2Report a problem
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3Report a problem
- Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabActive, not recruitingNCT04013854Phase 2Report a problem
- Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerActive, not recruitingNCT04013542Phase 1Report a problem
- A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2Report a problem
- Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 2Report a problem
- Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyWithdrawnNCT03982121Phase 1Report a problem
- Cryotherapy With in Situ Immunotherapy in Melanoma MetastasisCompletedNCT03949153Phase 1/2Report a problem
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaActive, not recruitingNCT03918252Phase 2Report a problem
- A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerStatus unknownNCT03879122Phase 2/3Report a problem
- NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2Report a problem
- An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)Status unknownNCT03823625Phase 2Report a problem
- Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseActive, not recruitingNCT03818685Phase 2Report a problem
- Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell CancerCompletedNCT03798639Phase 1Report a problem
- Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerActive, not recruitingNCT03776487Phase 2Report a problem
- Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2Report a problem
- RACIN in Patients With Advanced TIL-negative Solid TumorsCompletedNCT03728179Phase 1Report a problem
- Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of GlioblastomaTerminatedNCT03707457Phase 1Report a problem
- Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant TherapyActive, not recruitingNCT03700905Phase 3Report a problem